Drug Search Results
More Filters [+]

Angiotensin ii

Alternative Names: angiotensin ii, giapreza
Latest Update: 2024-09-26
Latest Update Note: Clinical Trial Update

Product Description

Angiotensin II is the main effector molecule of the RAS. It causes increases in blood pressure, influences renal tubuli to retain sodium and water, and stimulates aldosterone release from adrenal gland. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3377325/)

Mechanisms of Action: AT1 Agonist,AT2 Agonist

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Oral,Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Belgium | Croatia | Czech | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | Ireland | Italy | Latvia | Lithuania | Netherlands | Norway | Poland | Portugal | Romania | Russia | Slovakia | Slovenia | Sweden | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: Innoviva
Company Location: BURLINGAME CA 94010
Company CEO: Pavel Raifeld
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Angiotensin ii

Countries in Clinic: China, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: Acute Kidney Injury|Liver Transplant|Other|Vasoplegia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TQG3902-III-01

P3

Not yet recruiting

Other

2027-06-01

82%

AngLT-1

P3

Recruiting

Liver Transplant|Vasoplegia

2025-09-01

AIDED

P3

Active, not recruiting

Acute Kidney Injury

2022-05-16

Recent News Events